繁體
简体中文
繁體中文

iShares短期加州市政債券主動型ETF CALI 深 滬

已收盤 11-20 16:00:00 美东时间

50.1449

+0.050

+0.10%

华盛通華盛通
立即下載
  • 最 高50.1557
  • 今 開50.14
  • 成交量 25.53万股
  • 最 低 50.11
  • 昨 收 50.095
  • 總市值 70.70万
  • 52周最高 50.9833
  • 市盈率 靜 --
  • 換手率 1810.75%
  • 52周最低 49.274
  • 委 比 0.00%
  • 總股本 1.41万
  • 歷史最高 50.9833
  • 量 比 1.38
  • 振 幅 0.09%
  • 歷史最低 -4.662
  • 每 手 1
  • 風險率 0.24%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • Does Nike Revenue Slump Change The Bull Case For DICK'S Sporting Goods (DKS)?

    DICK'S Sporting Goods has already launched its first officially licensed collegiate collections from VRST, CALIA and DSG for Ohio State and Iowa, offering t-shirts, pants and layering pieces across men's, women's and youth in select stores and online. The new collegiate ranges expand DICK'S Sporting Goods vertical brands just as Nike, which supplies roughly 31% of its merchandise, signalled a multiyear revenue slump that could pressure athletic f

    今天 11:15

  • Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights

    Calidi Biotherapeutics reported progress on its CLD-401 program, presenting new data at the ESMO Congress 2026 and advancing its RedTail platform. The company raised $1.2 million through a registered direct offering and reduced general and administrative expenses by $1.0 million, or 39%, in the third quarter of 2026. The firm also announced a restructuring plan to save $3 million annually. Financially, Calidi reported a net loss of $3.6 million f...

    11-13 22:03

  • GT Biopharma Oral Presentation at the SITC 2026 Annual Meeting

    GT Biopharma presented new preclinical data at the SITC 2026 Annual Meeting, showing that combining GTB-5550, a B7-H3-targeted TriKE NK cell engager, with a KRAS inhibitor enhances NK cell cytotoxicity against pancreatic tumor cells. The combination improved tumor control, reduced metastasis, and increased NK cell infiltration in PDAC models. GT Biopharma is exploring a future Phase 1b study to evaluate this combination in pancreatic cancer patie...

    11-09 12:00

  • GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting

    GT Biopharma, Inc. has been selected for an oral presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. The presentation, titled "Inhibition of the KRAS oncoprotein sensitizes pancreatic cancer to NK cell immunotherapy," will be delivered by Paarth Dodhiawala on November 6, 2026. The session focuses on combination therapies involving cell therapy to enhance treatment effectiveness in solid tumors. GT Biopharma's TriKE...

    10-26 12:00